

WE CLAIM:

1. A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with a naphthalimide and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease.

5 2. The method according to claim 1, wherein said naphthalimide comprises amonafide (5-amino-2-[2-(dimethylamine)ethyl]-1H-benz[de]-isoquinoline-1,3-(2H)-dione).

3. The method according to claim 1, wherein said naphthalimide comprises a amonafide analog.

10 4. The method according to claim 1 wherein said antiproliferative agent comprises an agent that interacts with nucleic acids.

5. The method according to claim 1 wherein said antiproliferative agent comprises an alkylating agent, an intercalating agent, a metal coordination complex, a pyrimidine nucleoside, a purine nucleoside, an inhibitor of nucleic acid associated enzymes, or an inhibitor of nucleic acid associated proteins.

15 6. The method according to claim 1 wherein said antiproliferative agent comprises cisplatin.

7. A method according to claim 1 wherein said naphthalimide is administered before the administration of said antiproliferative agent.

8. A method according to claim 1 wherein said naphthalimide is administered during the administration of said antiproliferative agent.

20 9. A method according to claim 1 wherein said naphthalimide is administered after the administration of said antiproliferative agent.

10. The method of claim 1 wherein the modulation of said disease with said composition is greater than that for said antiproliferative agent alone.

11. A composition comprising a naphthalimide and an antiproliferative agent.
12. The composition of claim 11 wherein said naphthalimide comprises amonafide.
13. The composition of claim 11 wherein said antiproliferative agent comprises cisplatin, paclitaxel, vinblastine, etoposide, 5-fluorouracil, homoharringtonine, colchicine, curcumin, or parthenolide.
14. Use of a naphthalimide and an antiproliferative agent in the formulation of a medicament for the treatment of a cellular proliferative disease.